Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.49040
Abstract: Key Points Question Does targeting programmed cell death 1 or programmed cell death ligand 1 enhance the clinical benefits of anti–vascular endothelial growth factor therapy in patients with refractory metastatic colorectal cancer (mCRC)? Findings In… read more here.
Keywords: programmed cell; capecitabine bevacizumab; cell death; capecitabine ... See more keywords
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.77
Abstract: 77Background: MSS mCRC rarely responds to pembrolizumab monotherapy, but capecitabine and bevacizumab may induce immune-stimulatory effects. This study evaluates the safety, tolerability and prelim... read more here.
Keywords: study pembrolizumab; mcrc; mss; capecitabine bevacizumab ... See more keywords